(Q37304402)

19 August 2017

Relationship between tamoxifen use and high risk endometrial cancer histologic types (English)

1 reference

19 August 2017

1 reference

1 reference

8

Laura Havrilesky

1 reference

PubMed ID

18937966

19 August 2017

Angeles Alvarez Secord

series ordinal

3

object named as

Angeles Alvarez Secord

1 reference

19 August 2017

5

Fidel A Valea

1 reference

19 August 2017

6

Andrew Berchuck

1 reference

19 August 2017

1

Amy E Bland

1 reference

19 August 2017

2

Brian Calingaert

1 reference

19 August 2017

7

John T Soper

1 reference

19 August 2017

Paula S Lee

4

1 reference

PubMed ID

18937966

19 August 2017

language of work or name

English

0 references

publication date

19 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

112

1 reference

19 August 2017

1

1 reference

19 August 2017

150-154

1 reference

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Second cancers after adjuvant tamoxifen therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Tamoxifen and the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast–Ovarian Cancer Syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

BRCA1 germline mutations in women with uterine serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

Association between uterine serous carcinoma and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.08.035

10.1016/J.YGYNO.2008.08.035

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18937966